Table 1.
Management of primary intracranial Ewing sarcoma with metastasis
| Author, year | Age/sex | Tumor location | Location of metastasis | Resection | Radiation (Gy) | Chemotherapy regimen | Follow-up (mo) |
|---|---|---|---|---|---|---|---|
| Present case, 2020 | 37, M | Pineal region | Spinal cord | Biopsy | 36 | 4 weeks vincristine | No disease (7) |
| Chen et al, 20186 | 23, M | L TP, DB | Spinal cord | STR | 55 | None | Died (6) |
| Chen et al, 20186 | 22, F | R T | Skull | GTR | 55 | VAC | Died (38) |
| Chen et al, 20186 | 12, F | R T, L FP, DB | Diffuse metastasis | STR | 50 | VIDE | Died (20) |
| Alqahtani et al, 20177 | 3, M | PF | Spinal cord | GTR | NS | VIDE + C for 3 mo then VTI | Recurrence (8) |
| Tanboon et al, 20128 | 22, F | Frontal DB | Diffuse metastasis | GTR | None | None | Died (6 postop) |
| Mobley et al, 20069 | 21, M | O | Multiple vertebrae | Biopsy | 54 | Dactinomycin, VAC | Recurrence (18) |
| Jay et al, 19965 | 4, M | PF | Spinal cord | GTR | CSI, dose NS | VCE then ICE | Progression of LMS |
CSI indicates craniospinal irradiation; DB, dural-based; F, frontal; FP, frontoparietal; GTR, gross total resection; ICE, ifosfamide, carboplatin, etoposide, mesna; L, left; LMS, leptomeningeal spread; NS, not specified; O, occiput; PF, posterior fossa; R, right; STR, subtotal resection; T, temporal; TP, temporoparietal; VAC, vincristine, doxorubicin, cyclophosphamide; VCE, vincristine, cyclophosphamide, epirubicin; VIDE + C, vincristine, ifosfamide, doxorubicin, etoposide plus cyclophosphamide; VIDE, vincristine, ifosfamide, doxorubicin, etoposide; VTI, vincristine, temozolomide, irinotecan.